Comprehensive Population-Based Study Conducted by Team at The Cancer Institute of New Jersey
Newswise ? New Brunswick, N.J., January 17, 2013 ? In what is believed to be the first study to describe the impact on men with a ?high? risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion. The findings, published in the latest online version of BJU International (doi:10.1111/j.1464-410X.2012.11758.x), also show that men who experienced a fracture had a 1.38-fold higher mortality risk than those who did not. The Cancer Institute of New Jersey is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (RWJMS).
Men with localized prostate cancer who have underlying health conditions often receive this type of therapy with the hope to shrink or delay growth of their cancer, because they are considered inappropriate candidates for more aggressive therapies such as surgery or radiation. Previous studies have shown an association between the receipt of ADT for prostate cancer and an increased risk of bone fracture and other skeletal complications, such as a decrease in bone mineral density. The investigators at The Cancer Institute of New Jersey further explored the impact of this treatment on men already deemed to be at high risk for fracture prior to receiving therapy.
Using the population-based Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, researchers reviewed information on demographics and tumor characteristics from 75,994 men aged 66 and older who were diagnosed as having localized prostate cancer from 1992 to 2007. All of the SEER registries hold the highest level of certification of data quality. A risk assessment scale for baseline skeletal complications - including fracture - was created, utilizing the presence of certain conditions within one year prior to cancer diagnosis. These conditions included diabetes, alcohol and cigarette use, paralysis, and liver disease.
Investigators found that during a 12-year follow up, more than 58 percent of men deemed at high fracture risk prior to treatment and 38 percent considered at low risk developed at least one fracture following ADT. The research also showed that men with a high baseline risk had a higher probability of receiving ADT (52.1 percent) compared to those with a low baseline risk (38.2 percent). It was also determined that those men receiving ADT by itself were likely to have a stronger dose than those who received ADT in combination with other treatments for their prostate cancer. Mortality risk was found to be 40 percent higher within two years after experiencing a fracture.
?Our findings suggest that treating men having a high baseline risk of fracture with long-term androgen deprivation therapy may have serious adverse consequences,? said senior author Grace Lu-Yao, PhD, MPH, cancer epidemiologist at The Cancer Institute of New Jersey and professor of medicine at Robert Wood Johnson Medical School and of epidemiology at UMDNJ-School of Public Health. ?We anticipate the results of this study will prompt further examination of a patient?s baseline-risk of fracture and skeletal complications prior to administering this course of therapy.?
The authors note the use of bisphosphonates, which are effective in preventing bone loss in patients with prostate cancer receiving ADT, was not available in the SEER-Medicare linked data. Information regarding a patient?s height and weight, which can be considered risk factors for skeletal complications, also was not available. Data on men younger than 66 were not examined. Despite these limitations, Dr. Lu-Yao, says their investigation shines new light on a large subset of men who commonly receive ADT.
Along with Lu-Yao, the author team consists of Yu-Hsuan Shao, PhD, The Cancer Institute of New Jersey and UMDNJ-School of Public Health; Dirk F. Moore, PhD, Weichung Shih, PhD, Yong Lin, PhD, and Thomas L. Jang, MD, MPH, all The Cancer Institute of New Jersey and Robert Wood Johnson Medical School.
The study was supported by grants from the National Cancer Institute (R01 CA 116399) and (Cancer Center Support Grant - P30 CA072720-13); and the Robert Wood Johnson Foundation (60624).
About The Cancer Institute of New Jersey
The Cancer Institute of New Jersey (www.cinj.org) is the state?s first and only National Cancer Institute-designated Comprehensive Cancer Center dedicated to improving the detection, treatment and care of patients with cancer, and serving as an education resource for cancer prevention. Physician-scientists at The Cancer Institute of New Jersey engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. To make a tax-deductible gift to support The Cancer Institute of New Jersey, call 732-235-8614 or visit www.cinjfoundation.org. Follow us on Facebook at www.facebook.com/TheCINJ.
The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Medical Center, Carol G. Simon Cancer Center at Overlook Medical Center, and Cooper University Hospital. Affiliate Hospitals: CentraState Healthcare System, JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), Somerset Medical Center, The University Hospital/UMDNJ-New Jersey Medical School*, and University Medical Center of Princeton at Plainsboro. *Academic Affiliate
Comment/Share
'); if(ui.tab.hash == "#source") { //alert("Loading Source"); $('#source').load('/articles/related/?article_id=598206&source_id=5495&tab_selected='+(ui.panel.id)); } if(ui.tab.hash == "#channel") { //alert("Loading Channel"); $('#channel').load('/articles/related/?article_id=598206'+'&channel[]=9&channel_name[]=Cancer'+'&tab_selected='+(ui.panel.id)); } if(ui.tab.hash == "#tags") { //alert("Loading Tags"); $('#tags').load('/articles/related/?article_id=598206'+'&tag[]=3852&tag[]=46162&tag[]=41744&tag[]=103854&tag[]=3177&tag[]=53459&tag[]=16938&tag[]=27961&tag[]=28058'+'>&tab_selected='+(ui.panel.id)); } } //dump(ui.panel); }); function dump(obj) { var out = ''; for (var i in obj) { out += i + ": " + obj[i] + "\n"; } //alert(out); // or, to avoid alerts... var pre = document.createElement('pre'); pre.innerHTML = out; document.body.appendChild(pre) }
john elway i have a dream speech fox news debate school closures mlk mlk being human
No comments:
Post a Comment